Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Rangering i aksjer #36451
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aksjekurs
$1.73
Sist synkronisert: 2025-06-17
Markedsverdi
$2.55M
Endring (1 dag)
-0.29%
Endring (1 år)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)

Kategori

Healthcare
Antall utestående aksjer for Eiger BioPharmaceuticals, Inc. (EIGR)
Antall utestående aksjer per December 2023: 1.48M
Ifølge Eiger BioPharmaceuticals, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 1.48M. Ved slutten av December 2022 hadde selskapet 1.39M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Eiger BioPharmaceuticals, Inc. (EIGR) fra 2016 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 1.48M 0.22%
2023 1.48M 6.39%
2022 1.39M 22.64%
2021 1.13M 20.61%
2020 938.11K 23.51%
2019 759.52K 66.18%
2018 457.03K 57.09%
2017 290.93K 45.30%
2016 200.23K 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 17,061.24%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 26,665.85%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 32,269.92%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M 4,103.15%
NL